ECOG A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma<br> Adult CIRB - Late Phase Emphasis Closed to Accrual. Pts Still Rcving Intervention Available to Open